FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Investor's Business Daily on MSN30m
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Pharmaceutical Technology16m
NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...
Hosted on MSN53m
FDA approves new pain pill with potential to curb opioid addiction
The FDA has approved Vertex Pharmaceuticals' Journavx, a new pain medication that doesn't carry the risks of addiction and ...
Erie News Now22m
5 Things to know for Jan. 31: Plane collision, Confirmation hearings, Pain medicine, Japan sinkhole, FireAid benefit concerts
Here’s what else you need to know to Get Up to Speed and On with Your Day. Three of President Donald Trump’s most controversial picks for his Cabinet and key administration roles were grilled during ...
pharmaphorum18m
Exploring the future: Opportunities and challenges in cell and gene therapy for rare diseases
In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...
North American Morning Briefing: Investors in -2-
A midair collision between an American Airlines flight and an Army helicopter over the Potomac River killed all 67 people on the two aircraft, officials said Thursday, leaving investigators to piece ...